Riskpilot← Back to searchSign inGet full accessFerring Lääkkeet Oy
OYActiveY-tunnus 0625269-8Bertel Jungin Aukio 5Wholesale of pharmaceutical and medical goods · NACE 4646Est. 19865 employees
Revenue 2024
EUR 8,8M
-9% vs 2023
EBITDA margin
3.1%
-8% vs 2023
Equity ratio
21.6%
Financial strength
Net profit 2024
EUR 228K
-19% vs 2023
| Revenue | EUR 8,8M | -9% |
| EBITDA | EUR 276K | -8% |
| Net profit | EUR 228K | -19% |
| Total assets | EUR 3,4M | -11% |
| Equity | EUR 727K | -39% |
| Employees | 5 | — |
Legal name
Ferring Lääkkeet Oy
Y-tunnus number
0625269-8
Legal form
Osakeyhtiö
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
9. tammikuuta 1986
Share capital
EUR 40 000
Employees
5 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen jäsen ja toimitusjohtaja yhdessä sekä hallituksen jäsenet kaksi yhdessä
Company purpose
Föremål för bolagets verksamhet är försäljning och tillverkning av farmaceutiska- och hälsovårdsprodukter och preparat, härtill hörande marknadsundersökning samt annan härmed förenlig verksamhet.
Address
Bertel Jungin Aukio 5
Phone
+3580207401440
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 11 330 | 11 908 | 11 084 | 9 644 | 8 815 |
| Staff expenses | −1 046 | −355 | −488 | −600 | −702 |
| EBITDA | 1 000 | 456 | 399 | 299 | 276 |
| Depreciation & amort. | −10 | −2 | −2 | −2 | −0 |
| EBIT | 990 | 454 | 397 | 298 | 276 |
| Net financials | 22 | −2 | 46 | 76 | 36 |
| Profit before tax | 1 012 | 452 | 443 | 374 | 312 |
| Tax | 219 | 94 | 100 | 92 | 84 |
| Net profit | 793 | 358 | 342 | 282 | 228 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 4 406 | 5 097 | 4 189 | 3 777 | 3 362 |
| Equity | 918 | 576 | 918 | 1 199 | 727 |
| Long-term debt | 28 | 55 | 183 | 0 | 0 |
| Short-term debt | 3 459 | 4 466 | 3 088 | 2 578 | 2 634 |
| Total debt | 3 487 | 4 521 | 3 272 | 2 578 | 2 634 |
EBITDA margin
3.1%
This company
15.8%
Market median
-80% vs market
20202024
Equity ratio
21.6%
This company
38.2%
Market median
-43% vs market
20202024
Return on equity
31.3%
This company
18.4%
Market median
+70% vs market
20202024
Net profit margin
2.6%
This company
8.1%
Market median
-68% vs market
20202024
Asset turnover
2.62×
This company
1.12×
Market median
+134% vs market
20202024
Debt / equity
3.62×
This company
0.62×
Market median
-484% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
MV Person with significant control | Person with significant control | 2021 |
EM Deputy Member | Deputy Member | 2025 |
ML Chief Executive Officer | Chief Executive Officer | 2024 |
| Former (6) | ||
GR Person with significant control | Person with significant control | 2021 – 2025 |
CP Chief Executive Officer | Chief Executive Officer | 2021 – 2021 |
AJ Audit | Audit | 2021 – 2023 |
JR Deputy Member | Deputy Member | 2025 – 2025 |
AK Audit | Audit | 2018 – 2021 |
LM Chief Executive Officer | Chief Executive Officer | 2013 – 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2024 | |
| Former (4) | ||
| Board of Directors | 2021 – 2021 | |
| Board of Directors | 2018 – 2021 | |
| Board of Directors | 2021 – 2024 | |
| Board of Directors | 2021 – 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Ferring Lääkkeet Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Morten Vaupel | Person with significant control | 0 companies |
| Gianpiero Reverberi | Person with significant control | 0 companies |
| Claes Peter Marcusson | Chief Executive Officer | 0 companies |
| Antti Juhani Rönkkö | Audit | 0 companies |
| Eric Michel Breumier | Deputy Member | 0 companies |
| Jenise Ryann Doutsas | Deputy Member | 0 companies |
| Anu Kaarina Servo | Audit | 0 companies |
| Leena Marjukka Suomela | Chief Executive Officer | 0 companies |
| Maja Lassenius Kramp | Chief Executive Officer | 0 companies |
| Lasse Juul Jakobsen | Board of Directors | 0 companies |
| Mario Alejandro Esteves Durand | Board of Directors | 0 companies |
| Cristiano Ferreira | Board of Directors | 0 companies |
| Valerio Trifoni | Board of Directors | 0 companies |
| Tomi Olavi Ekholm | Board of Directors | 0 companies |